Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04432207 : An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

OnePhase One

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Treatment | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase I trial is evaluating the safety and tolerability of a new type of immunotherapy, given alone or with standard of care treatment, in patients with PD-L1 non-small cell lung cancer.
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Commercial Sponsor

Imugene Limited

Summary

This is a dose escalation and expansion trial. Dose escalation will occur across three monotherapy cohorts (10 μg/dose, 50 μg/dose and 100μg/dose IMU-201 as a 0.5 mL PD1-Vaxx injection)and one combination cohort, in which patients will receive standard of care treatment for non-small cell lung cancer in combination with MU-201 at a starting dose below the monotherapy optimal biological dose. Dose expansion will commence once an optimal biological dose of MU-201 is determined in the combination cohort of the dose escalation phase. Patients enrolled in the expansion cohort will receive IMU-201 in combination with standard of care treatment for non-small cell lung cancer.

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Li Hoon Lai
lihoonlai@cabrini.com.au
(03) 9508 3421

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next